Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non–small-cell lung cancer: KEYNOTE-189 Japan Study

43Citations
Citations of this article
64Readers
Mendeley users who have this article in their library.

Abstract

Pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) with manageable safety compared with placebo plus pemetrexed-platinum in patients with previously untreated metastatic nonsquamous non–small-cell lung cancer (NSCLC) without EGFR/ALK alterations in the global, randomized, double-blind, phase 3 KEYNOTE-189 study. We present results of Japanese patients enrolled in the KEYNOTE-189 global and Japan extension studies. Patients were randomized 2:1 to intravenous pembrolizumab 200 mg or placebo every 3 weeks (Q3W) for up to 35 cycles. All patients received pemetrexed 500 mg/m2 plus the investigator’s choice of cisplatin or carboplatin Q3W for four cycles, followed by maintenance pemetrexed 500 mg/m2 Q3W (all intravenous). Co–primary endpoints were OS and PFS. Forty Japanese patients enrolled (pembrolizumab, n = 25; placebo, n = 15). At data cutoff (20 May 2019; median time from randomization to data cutoff, 18.5 [range, 14.7‒38.2] months), the median OS was not reached in the pembrolizumab plus pemetrexed-platinum arm; the median OS was 25.9 (95% confidence interval [CI], 11.9‒29.0) months in the placebo plus pemetrexed-platinum arm (hazard ratio [HR].29; 95% CI,.07‒1.15). The median (95% CI) PFS was 16.5 (8.8‒21.1) compared with 7.1 (4.7‒21.4) months (HR,.62; 95% CI,.27‒1.42), respectively. There were no grade 5 adverse events (AE). Grade 3/4 AE occurred in 72% vs 60% of patients in the pembrolizumab vs placebo arms; 40% vs 20% had immune-mediated AE, and 4% vs 0% had infusion reactions. Efficacy and safety outcomes were similar to those from the global study and support first-line therapy with pembrolizumab plus pemetrexed-platinum in Japanese patients with nonsquamous NSCLC without EGFR/ALK alterations.

References Powered by Scopus

Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer

5105Citations
N/AReaders
Get full text

Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer

2880Citations
N/AReaders
Get full text

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study

1959Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

147Citations
N/AReaders
Get full text

Immunotherapy or Chemoimmunotherapy in Older Adults with Advanced Non-Small Cell Lung Cancer

21Citations
N/AReaders
Get full text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

20Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Horinouchi, H., Nogami, N., Saka, H., Nishio, M., Tokito, T., Takahashi, T., … Kurata, T. (2021). Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non–small-cell lung cancer: KEYNOTE-189 Japan Study. Cancer Science, 112(8), 3255–3265. https://doi.org/10.1111/cas.14980

Readers over time

‘21‘22‘23‘24‘2506121824

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

61%

Researcher 5

28%

Lecturer / Post doc 2

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

50%

Nursing and Health Professions 6

27%

Pharmacology, Toxicology and Pharmaceut... 3

14%

Engineering 2

9%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0